HYPOSENSITIZATION THERAPY FOR NASAL ALLERGY WITH PASPAT

Abstract

Paspat contains autolytic products of streptococci, staphylococci, pneumococci, tuberculin and methylephedrine.
56.3% of 295 patients with nasal allergy showed positive skin reaction to Paspat. 60% of 129 patients who had responded positively to Paspat skin test showed positive reaction to nasal provocative testing with 10% Paspat.
Thirty six patients who had responded positively to Paspat in both skin and nasal provocative tests were treated with Paspat hyposensitization. 0.2 ml of Paspat was administered intradermally once a week. Twenty-three patients were treated with Paspat plus house dust. The patients in the latter group had responded only to both Paspat and house dust in skin and nasal tests. Paspat was administered in the same manner and house dust was given with the regular hyposensitizing program. Thirty-one patients who had showed positive reaction only to house dust in both tests were treated with house dust hyposensitization and served as control. The efficacy of the treatment was evaluated by the change of symptoms. Percentages of successful hyposensitization in the 3 groups were 64.4%, 69.6% and 74.2%, respectively. The difference was not statistically significant. The results indicate that Paspat is a specific antigen leading to hyposensitization in patients who are sensitive to Paspat.
The size of skin reaction to Paspat and house dust was measured during the course of hyposensitization in the 3 groups. The changes in size of skin reaction was not statistically significant between the 3 groups. The change in the number of eosinophils in nasal secretion was not statistically significant during the course of hyposensitization in the 3 groups. These facts suggest that Paspat did not faciliate formation of blocking antibody against house dust.